Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data

Antonia Morga,Lisa Zimmermann,Udaya Valluri,Emad Siddiqui,Lori McLeod,Randall H. Bender
DOI: https://doi.org/10.1007/s12325-024-02849-2
2024-05-23
Advances in Therapy
Abstract:Vasomotor symptoms (VMS), the characteristic symptoms of menopausal transition, are often the primary reason women seek treatment. Current treatment options for VMS include fezolinetant, a nonhormonal, selective neurokinin 3 receptor antagonist. This study aimed to define a clinically meaningful threshold for reduction of moderate-to-severe VMS in postmenopausal women treated with fezolinetant and then apply it in a responder analysis of the pooled trial data.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?